{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:38:42Z","timestamp":1794483522254,"version":"4.9.1"},"reference-count":34,"publisher":"SAGE Publications","issue":"13","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["CrossRef Funder ID: 10.13039\/100009945"],"award-info":[{"award-number":["CrossRef Funder ID: 10.13039\/100009945"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The Phase IV MAGNIFY-MS Extension study evaluated the long-term efficacy and durability of cladribine tablets (CladT) in participants with highly active relapsing multiple sclerosis (RMS) during treatment-free Years (Y) 3 and 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were analysed for all participants and by subgroups (treatment-na\u00efve vs experienced). Time to no evidence of disease activity (NEDA-3) and first confirmed Symbol Digit Modalities Test (SDMT) score change (\u2a7e4\/8 point improvement or \u2a7d4\/8 point worsening) were assessed using Kaplan\u2013Meier analysis. SDMT changes were confirmed if sustained across two visits \u2a7e166\u2009days apart; others were classified as stable. Percentage brain volume change (PBVC) was analysed using the SIENA-XL method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 270 MAGNIFY-MS participants, 219 entered MAGNIFY-MS Extension (64.8% female; mean age\u2009\u00b1\u2009standard deviation: 40.4\u2009\u00b1\u20099.45\u2009years). NEDA-3 rates were 78.6% (Y3), 79.2% (Y4) and 54.2% (Y3\u2013Y4 combined). At Y4, 83.1% had no T1 gadolinium-enhancing lesions, 67.4% had no active T2 lesions, and the annualised relapse rate was 0.09. Mean annualised PBVC was &lt;0.4% in Y4. SDMT scores were 4\/8-point stable or improved in 79.0%\/88.1% of participants, and 84.5% had no 6-month confirmed disability progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Two years of short-course CladT provided sustained clinical and cognitive benefits, supporting the potential for treatment-free remission in RMS.<\/jats:p>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      Identifier: NCT04783935. Date registered: 3 March, 2021\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261467624","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:20:23Z","timestamp":1785828023000},"page":"1406-1420","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-7639","authenticated-orcid":false,"given":"Nicola","family":"De Stefano","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institute of Translational Neurology, University of M\u00fcnster, M\u00fcnster, Germany; Department of Neurology and Neurophysiology, Freiburg University, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Queen Square Institute of Neurology and UCL Hawkes Institute, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Centre d\u2019Esclerosi M\u00faltiple de Catalunya (Cemcat), Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Achiron","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-8769","authenticated-orcid":false,"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[{"name":"Experimental Neurophysiology, University Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[{"name":"The Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Faculty of Medicine &amp; Dentistry, Queen Mary University of London, London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[{"name":"Danish MS Center, Department of Neurology, Copenhagen University Hospital\u2013Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[{"name":"Global Patient Safety\/Safety Strategy, Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Petit","sequence":"additional","affiliation":[{"name":"Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-7557","authenticated-orcid":false,"given":"Dimitri","family":"Guala","sequence":"additional","affiliation":[{"name":"Clinical Measurement Sciences, Merck AB, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sponton","sequence":"additional","affiliation":[{"name":"Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gardner","sequence":"additional","affiliation":[{"name":"Neurology &amp; Immunology Medical Unit, EMD Serono Research &amp; Development Institute, Inc., Billerica, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00339-7"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512189"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251351760"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520921087"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420922685"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2021.12.016"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27096"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.23828"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0314-x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51302"},{"issue":"1","key":"e_1_3_5_15_2","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano N","year":"2016","unstructured":"De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87(1): 93\u201399.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_5_16_2","unstructured":"Merck. MAVENCLAD 10 mg tablets SmPC 2024 https:\/\/www.medicines.org.uk\/emc\/product\/8435\/smpc (accessed 17 January 2025)."},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049392"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106122"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15171"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211035740"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.610"},{"key":"e_1_3_5_22_2","first-page":"327","article-title":"P289 efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO","volume":"28","author":"Oreja-Guevara C","year":"2022","unstructured":"Oreja-Guevara C, Benedict RH, Comi G, et al. P289 efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO. Mult Scler J 2022; 28: 327\u2013328.","journal-title":"Mult Scler J"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418773025"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113321"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15579"},{"key":"e_1_3_5_26_2","first-page":"51","article-title":"P070 improved cognitive processing speed in patients treated with cladribine tablets for multiple sclerosis: MAGNIFY-MS 2-year findings","volume":"30","author":"Vermersch P","year":"2024","unstructured":"Vermersch P, Wiendl H, Barkhof F, et al. P070 improved cognitive processing speed in patients treated with cladribine tablets for multiple sclerosis: MAGNIFY-MS 2-year findings. Mult Scler J 2024; 30: 51\u201352.","journal-title":"Mult Scler J"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103405"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049397"},{"key":"e_1_3_5_29_2","first-page":"392","article-title":"P377 cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data","volume":"28","author":"Benedict RH","year":"2022","unstructured":"Benedict RH, Comi G, Oreja-Guevara C, et al. P377 cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data. Mult Scler J 2022; 28: 392.","journal-title":"Mult Scler J"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30277-5"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001285"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70149"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200052"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261467624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261467624","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261467624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:18:40Z","timestamp":1794482320000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261467624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/13524585261467624"],"URL":"https:\/\/doi.org\/10.1177\/13524585261467624","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}